Annual Total Long Term Liabilities
$540.83 M
+$47.22 M+9.57%
December 31, 2023
Summary
- As of February 7, 2025, RVNC annual total long term liabilities is $540.83 million, with the most recent change of +$47.22 million (+9.57%) on December 31, 2023.
- During the last 3 years, RVNC annual total long term liabilities has risen by +$255.87 million (+89.79%).
- RVNC annual total long term liabilities is now at all-time high.
Performance
RVNC Long Term Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Long Term Liabilities
$544.54 M
+$13.64 M+2.57%
September 30, 2024
Summary
- As of February 7, 2025, RVNC quarterly total long term liabilities is $544.54 million, with the most recent change of +$13.64 million (+2.57%) on September 30, 2024.
- Over the past year, RVNC quarterly long term liabilities has dropped by -$11.98 million (-2.15%).
- RVNC quarterly long term liabilities is now -2.15% below its all-time high of $556.53 million, reached on September 30, 2023.
Performance
RVNC Quarterly Long Term Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Long Term Liabilities Formula
Long-Term Liabilities = Long-Term Debt + Deferred Tax Liabilities + Pension Liabilities + Other Long-Term Liabilities
RVNC Long Term Liabilities Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +9.6% | -2.1% |
| 3 y3 years | +89.8% | +37.6% |
| 5 y5 years | +1009.3% | +577.5% |
RVNC Long Term Liabilities Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | at high | +36.8% | -2.1% | +37.7% |
| 5 y | 5-year | at high | +632.7% | -2.1% | +637.7% |
| alltime | all time | at high | +9123.0% | -2.1% | +9596.3% |
Revance Therapeutics Long Term Liabilities History
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2024 | - | $544.54 M(+2.6%) |
| Jun 2024 | - | $530.90 M(-1.3%) |
| Mar 2024 | - | $537.89 M(-0.5%) |
| Dec 2023 | $540.83 M(+9.6%) | $540.83 M(-2.8%) |
| Sep 2023 | - | $556.53 M(+12.1%) |
| Jun 2023 | - | $496.67 M(+0.0%) |
| Mar 2023 | - | $496.49 M(+0.6%) |
| Dec 2022 | $493.62 M(+24.8%) | $493.62 M(+0.5%) |
| Sep 2022 | - | $491.15 M(+0.8%) |
| Jun 2022 | - | $487.29 M(-10.2%) |
| Mar 2022 | - | $542.94 M(+37.3%) |
| Dec 2021 | $395.40 M(+38.8%) | $395.40 M(-0.1%) |
| Sep 2021 | - | $395.79 M(-0.2%) |
| Jun 2021 | - | $396.39 M(+4.1%) |
| Mar 2021 | - | $380.86 M(+33.7%) |
| Dec 2020 | $284.97 M(+286.0%) | $284.97 M(+3.4%) |
| Sep 2020 | - | $275.64 M(+1.2%) |
| Jun 2020 | - | $272.47 M(+12.2%) |
| Mar 2020 | - | $242.92 M(+229.1%) |
| Dec 2019 | $73.82 M(+51.4%) | $73.82 M(-8.2%) |
| Sep 2019 | - | $80.38 M(+28.3%) |
| Jun 2019 | - | $62.65 M(-9.6%) |
| Mar 2019 | - | $69.30 M(+42.1%) |
| Date | Annual | Quarterly |
|---|---|---|
| Dec 2018 | $48.76 M(+719.2%) | $48.76 M(+154.7%) |
| Sep 2018 | - | $19.14 M(-8.6%) |
| Jun 2018 | - | $20.94 M(-16.7%) |
| Mar 2018 | - | $25.14 M(+322.4%) |
| Dec 2017 | $5.95 M(-22.1%) | $5.95 M(+5.3%) |
| Sep 2017 | - | $5.65 M(-0.6%) |
| Jun 2017 | - | $5.69 M(-15.7%) |
| Mar 2017 | - | $6.74 M(-11.8%) |
| Dec 2016 | $7.64 M(-27.4%) | $7.64 M(-11.4%) |
| Sep 2016 | - | $8.63 M(-7.4%) |
| Jun 2016 | - | $9.31 M(-3.6%) |
| Mar 2016 | - | $9.66 M(-8.3%) |
| Dec 2015 | $10.53 M(+79.6%) | $10.53 M(-7.8%) |
| Sep 2015 | - | $11.42 M(-6.5%) |
| Jun 2015 | - | $12.22 M(+109.3%) |
| Mar 2015 | - | $5.84 M(-0.5%) |
| Dec 2014 | $5.86 M(-95.6%) | $5.86 M(-6.3%) |
| Sep 2014 | - | $6.26 M(+3.6%) |
| Jun 2014 | - | $6.04 M(+7.6%) |
| Mar 2014 | - | $5.62 M(-95.8%) |
| Dec 2013 | $132.63 M(+18.2%) | $132.63 M(+1298.0%) |
| Sep 2013 | - | $9.49 M(-91.5%) |
| Dec 2012 | $112.22 M(-39.8%) | $112.22 M |
| Dec 2011 | $186.56 M | - |
FAQ
- What is Revance Therapeutics annual total long term liabilities?
- What is the all time high annual total long term liabilities for Revance Therapeutics?
- What is Revance Therapeutics annual total long term liabilities year-on-year change?
- What is Revance Therapeutics quarterly total long term liabilities?
- What is the all time high quarterly long term liabilities for Revance Therapeutics?
- What is Revance Therapeutics quarterly long term liabilities year-on-year change?
What is Revance Therapeutics annual total long term liabilities?
The current annual total long term liabilities of RVNC is $540.83 M
What is the all time high annual total long term liabilities for Revance Therapeutics?
Revance Therapeutics all-time high annual total long term liabilities is $540.83 M
What is Revance Therapeutics annual total long term liabilities year-on-year change?
Over the past year, RVNC annual total long term liabilities has changed by +$47.22 M (+9.57%)
What is Revance Therapeutics quarterly total long term liabilities?
The current quarterly long term liabilities of RVNC is $544.54 M
What is the all time high quarterly long term liabilities for Revance Therapeutics?
Revance Therapeutics all-time high quarterly total long term liabilities is $556.53 M
What is Revance Therapeutics quarterly long term liabilities year-on-year change?
Over the past year, RVNC quarterly total long term liabilities has changed by -$11.98 M (-2.15%)